NetScientific plc (GB:NSCI) has released an update.
NetScientific plc announced that its portfolio company, PDS Biotechnology, reported promising results from the Phase 2 VERSATILE-002 trial using their Versamune® HPV treatment in combination with KEYTRUDA® for head and neck cancer, outperforming previous therapies. The company also expanded its global intellectual property portfolio and reported a net loss of $10.6 million for Q1 2024, while maintaining a strong cash position with $66.6 million in cash and cash equivalents.
For further insights into GB:NSCI stock, check out TipRanks’ Stock Analysis page.
